

Helena Vila-Reyes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3841098/publications.pdf>

Version: 2024-02-01

19
papers

166
citations

1683354

5
h-index

1719596

7
g-index

20
all docs

20
docs citations

20
times ranked

176
citing authors

#	ARTICLE	IF	CITATIONS
1	Obesity in Percutaneous Nephrolithotomy. Is Body Mass Index Really Important?. <i>Urology</i> , 2014, 84, 538-543.	0.5	54
2	Comparison of biopsy devices in upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2019, 37, 1899-1905.	1.2	36
3	Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Centre Prospective Non-Randomized Trial. <i>Journal of Endourology</i> , 2020, 34, 573-580.	1.1	31
4	Carcinoma In Situ of the Urinary Bladder: A Systematic Review of Current Knowledge Regarding Detection, Treatment, and Outcomes. <i>European Urology Focus</i> , 2020, 6, 674-682.	1.6	21
5	The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 565086.	1.3	20
6	Re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. <i>Eur Urol</i> 2020;77:636-43. <i>Eur Urol</i> 2020;77:e158. <i>European Urology</i> , 2021, 79, e35-e36.	0.9	3
7	Oncologic outcomes of complete transurethral resection prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17029-e17029.	0.8	1
8	MP79-17 FOLLOW UP AFTER 4 YEARS OF URETERAL STENOSIS IN TRANSPLANT KIDNEY MANAGED WITH LONG-TERM THERMO-EXPANDABLE METALLIC STENT. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
9	MP38-17 LAPAROASSISTED PERCUTANEOUS NEPHROLITHOTOMY: EXPERIENCE AND OUTCOMES. <i>Journal of Urology</i> , 2015, 193, . Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2021, 79, e54-e55.	0.2	0
10	Future role of [18F]-FDG PET/CT in patients with bladder cancer in the new era of neoadjuvant immunotherapy? <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 139-141.	0.9	0
11	Utility of Routine Preoperative 18 F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy. Letter.. <i>Journal of Urology</i> , 2021, 206, 169-170.	0.8	0
12	The Role of Cost-Effectiveness Analysis in Patient-Centered Cancer Care in the Era of Precision Medicine. <i>Cancers</i> , 2021, 13, 4272.	0.2	0
13	MP13-20's LONG TERM OUTCOMES IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER WHO ARE MISCLASSIFIED AS ACHIEVING A COMPLETE CLINICAL RESPONSE TO NEOADJUVANT CHEMOTHERAPY: HOW COSTLY ARE MISTAKES?. <i>Journal of Urology</i> , 2021, 206, .	1.7	0
14	Laparoscopic Sigmoid Colectomy for Diverticular Disease. <i>Diseases of the Colon and Rectum</i> , 2021, Publish Ahead of Print, e78-e79.	0.2	0
15	MP50-04's ADJUVANT SINGLE-DOSE UPPER URINARY TRACT INSTILLATION OF MITOMYCIN C AFTER THERAPEUTIC URETEROSCOPY FOR UPPER TRACT UROTHELIAL CARCINOMA: PRELIMINARY RESULTS. <i>Journal of Urology</i> , 2019, 201, .	0.7	0
16	MP13-03's FACTORS ASSOCIATED WITH FALSE-NEGATIVE MPMRI (PIRADS 1) OF THE PROSTATE IN PATIENTS UNDERGOING BIOPSY FOR SUSPICION OF PROSTATE CANCER. <i>Journal of Urology</i> , 2020, 203, e185.	0.2	0
17	PD60-04's SURVIVAL ANALYSIS AND PREDICTORS OF NON-MUSCLE INVASIVE BLADDER CANCER RECURRENCE IN CLINICAL COMPLETE-RESPONDERS AFTER NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2020, 203, e1274.	0.2	0
18			

#	ARTICLE	IF	CITATIONS
19	MP73-09â€fEFFECTIVENESS OF COMBINATION CISPLATIN-BASED INTRAVESICAL CHEMOTHERAPY FOR BCG-REFRACTORY BLADDER CANCER. Journal of Urology, 2020, 203, .	0.2	0